TD Cowen Reiterates Buy Rating on Cullinan Oncology Inc. (CGEM)

TD Cowen analyst Marc Frahm reiterated a Buy rating on Cullinan Oncology Inc. (NASDAQ: CGEM).

The analyst commented, "At ESMO, CGEM presented updated data from Module C of the REZILIENT-1 Ph IIb trial of zipalertinib (EGFR exon20ins TKI) in post-ami EGFR exon20ins NSCLC. Efficacy in the 2L+ post-ami setting was similar to Ph I/IIa data in post-chemo patients (ORR=40% vs. 39%) suggesting different resistance mechanisms. The discussant praised zipa's safety as also offering potential for ami combo. Remain Buy."

For an analyst ratings summary and ratings history on Cullinan Oncology Inc. click here. For more ratings news on Cullinan Oncology Inc. click here.

Shares of Cullinan Oncology Inc. closed at $17.95 yesterday.

You May Also Be Interested In

• Cullinan Oncology Inc. (CGEM) PT Raised to $27 at UBS
• PicPay integrates ChatGPT to let users query account data
• Rocket Lab joins U.S. Space Force's $981M NITE-STAR contract